Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma
Corresponding Author
Dr. Carlos Barrios
Department of Orthopeaics, Karolinska Hospital, Stocholm, Sweden
Orthopedics and Trauma Institute, Clínica Quirón, Blasco Ibañez 14, 46010 Valencia, SpainSearch for more papers by this authorJavier S. Castresana
Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Boston, Massachusetts, U.S.A.
Search for more papers by this authorJuan Ruiz
Department of Tumor Pathology, Karolinska Hospital, Stocholm, Sweden
Search for more papers by this authorAndris Kreicbergs
Department of Orthopeaics, Karolinska Hospital, Stocholm, Sweden
Search for more papers by this authorCorresponding Author
Dr. Carlos Barrios
Department of Orthopeaics, Karolinska Hospital, Stocholm, Sweden
Orthopedics and Trauma Institute, Clínica Quirón, Blasco Ibañez 14, 46010 Valencia, SpainSearch for more papers by this authorJavier S. Castresana
Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Boston, Massachusetts, U.S.A.
Search for more papers by this authorJuan Ruiz
Department of Tumor Pathology, Karolinska Hospital, Stocholm, Sweden
Search for more papers by this authorAndris Kreicbergs
Department of Orthopeaics, Karolinska Hospital, Stocholm, Sweden
Search for more papers by this authorAbstract
The genomic organization of four oncogenes, c-myc, c-myb, c-Ha-ras, and v-fms, was analyzed in 21 patients with malignant bone tumors. Amplification of the c-myc proto-oncogene without rearrangement was the sole abnormality detected in four tumors: two chondrosarcomas, one osteosarcoma, and one lymphoma of bone. DNA hybridizations with c-myb, c-Ha-ras, and v-fms probes disclosed no structural gene abnormalities. Point mutations at the 12th codon of the c-Ha-ras gene were investigated with the polymerase chain reaction technique; no alterations were detected. The observed amplification of the c-myc there was not related to histologic type, grade, surgical stage, or ploidy level of the tumors. The results indicated that c-myc amplification, presumed to be involved in the development of malignancy in a variety of solid tumors, is encountered sporadically in malignant bone tumors; however, this occurs without relation to common histopathologic features. The clinical significance of oncogene amplification in bone sarcoma remains to be established.
References
- 1 Alitalo K, Schwab M: Oncogene amplification in tumor cells. Adv Cancer Res 47: 235–281, 1985
- 2 Asano S, Yamashita T: [Analysis of cellular oncogenes in human osteosarcomas transplanted into nude mice]. Nippon Seikeigeka Gakkai Zasshi 62: 231–242, 1988
- 3 Barbacid M: Oncogenes and human cancer: cause or consequence? Carcinogenesis 7: 1037–1042, 1986
- 4 Bishop JM: The molecular genetics of cancer. Science 235: 305–311, 1987
- 5 Bonilla M, Ramirez M, López-Cueto J, Gariglio P: In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst 80: 665–671, 1988
- 6 Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293–297, 1987
- 7 Bos JL: Ras oncogene in human cancer: a review. Cancer Res 49: 4682–4689, 1989
- 8 Broders AC, Hargrave R, Meyerding HW: Pathological features of soft tissue fibrosarcoma: with special reference to the grading of its malignancy. Surg Gynecol Obstet 69: 267–280, 1939
- 9 Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124, 1984
- 10 Chang EH, Furth ME, Scolnik EM, Lowy DR: Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297: 479–483, 1982
- 11
Cline MJ,
Battifora H:
Abnormalities of protooncogenes in non-small cell lung cancer: correlations with tumor type and clinical characteristics.
Cancer
60:
2669–2674,
1987
10.1002/1097-0142(19871201)60:11<2669::AID-CNCR2820601116>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 12 Coussens L, Van Beveren C, Smith D, Chen E, Mitchell RJ, Isacke CM, Verma IM, Ullrich A: Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature 320: 277–280, 1986
- 13 Dahlin DC: Pathology of osteosarcoma. Clin Orthop 111: 23–32, 1975
- 14 Deng GR: A sensitive non-radioactive PCR-RFLP analysis for detecting point mutations at 12th codon of oncogene c-Ha-ras in DNAs of gastric cancer. Nucleic Acids Res 16: 6231, 1988
- 15 Deng GR, Liu XH, Wang JR: Correlation of mutations of oncogene c-Ha-ras at codon 12th with metastasis and survival of gastric cancer patients. Oncogene Res 6: 33–38, 1991
- 16 Enneking WF: A system of staging musculoskeletal neoplasms. Clin Orthop 204: 9–24, 1986
- 17 Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R: Genetic alteration of the c-myc proto-oncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A 83: 4834–4838, 1986
- 18 Feinberg AP, Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity [addendum]. Anal Biochem 137: 266–267, 1984
- 19 Grody WW, Gatti RA, Naeim F: Diagnostic molecular pathology. Mod Pathol 2: 553–568, 1989
- 20 Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y: Amplification of the c-myc and c-erb B-2 protooncogenes in human solid tumors: frequency and clinical significance. Int J Cancer 44: 802–805, 1989
- 21 Hayashi K, Kakizoe T, Sugimura T: In vivo amplification and rearrangement of the c-Ha-ras-1 sequence in a human bladder carcinoma. Jpn J Cancer Res 74: 798–801, 1983
- 22 Hollstein MC, Smits AM, Galiana C, Yamasaki H, Bos JL, Mandard A, Partridge C, Montesano R: Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res 48: 5119–5123, 1988
- 23 Iglehart JD, Kraus MH, Langton BC, Huper G, Kems BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701–6707, 1990
- 24 Ikeda S, Sumii H, Akiyama K, Watanabe S, Ito S, Inoue H, Takechi H, Tanabe G, Oda T: Amplification of both c-myc and c-raf-1 oncogenes in human oteosarcoma. Jpn J Cancer Res 80: 6–9, 1989
- 25 Johnson BE, Ihde DC, Makuch RW, Gazdar AF, Carney DN, Oie H, Russell E, Nau MM, Minna JD: Myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 79: 1629–1634, 1987
- 26 Kafatos FC, Jones CW, Efstratiadis A: Determination of nucleic acid sequence homologies and relative concentrations by a dot hybridization procedure. Nucleic Acids Res 7: 1541–1552, 1979
- 27 Kato M, Toguchida J, Honda K, Sasaki MS, Ikenaga M, Sugimoto M, Yamaguchi T, Kotoura Y, Yamamuro T, Ishizaki K: Elevated frequency of a specific allele of the L-myc gene in male patients with bone and soft-tissue sarcomas. Int J Cancer 45: 47–49, 1990
- 28
Kreicbergs A,
Tribukait B,
Willems J,
Bauer HC:
DNA flow analysis of soft tissue tumors.
Cancer
59:
128–133,
1987
10.1002/1097-0142(19870101)59:1<128::AID-CNCR2820590126>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
- 29 Majello B, Kenyon LC, Dalla-Favera R: Human c-myb proto-oncogene: nucleotide sequence of cDNA and organization of the genomic locus. Proc Natl Acad Sci U S A 83: 9636–9640, 1986
- 30 Masuda H, Battifora H, Yokota J, Meltzer S, Cline MJ: Specificity of proto-oncogene amplification in human malignant diseases. Mol Biol Med 4: 213–227, 1987
- 31 Meltzer SJ, Ahnen DJ, Battifora H, Yokota J, Cline MJ: Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 92: 1174–1180, 1987
- 32 Miyaki M, Sato C, Matsui T, Koike M, Mori T, Kosaki G, Takai S, Tonomura A, Tsuchida N: Amplification and enhanced expression of cellular oncogene c-Ki-ras-2 in a human epidermoid carcinoma of the lung. Jpn J Cancer Res 76: 260–265, 1985
- 33 Mulligan LM, Matlashewski GJ, Scrabel HJ, Cavenee WK: Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A 87: 5863–5867, 1990
- 34
O'Neal LW,
Ackerman LV:
Chondrosarcoma of bone.
Cancer
5:
551–577,
1952
10.1002/1097-0142(195205)5:3<551::AID-CNCR2820050317>3.0.CO;2-Z PubMed Web of Science® Google Scholar
- 35 Reissmann PT, Simon MA, Lee WH, Slamon DJ: Studies of the retinoblastoma gene in human sarcomas. Oncogene 4: 839–843, 1989
- 36 Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M: Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 48: 161–164, 1988
- 37 Rothberg PG, Erisman MD, Diehl RE, Rovigatti UG, Astrin SM: Structure and expression of the oncogene c-myc in fresh tumor material from patients with hematopoietic malignancies. Mol Cell Biol 4: 1096–1103, 1984
- 38 Ruther U, Komitowski D, Schubert FR, Wagner EF: C-fos expression induces bone tumors in transgenic mice. Oncogene 4: 861–865, 1989
- 39 Schajowicz F, Ackerman LV, Sissons HA: Histological typing of bone tumors. International Histological Classification of Tumors. No. 6. Geneva, World Health Organization, 1972
- 40 Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM: Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A 81: 4940–4944, 1984
- 41 Schwab M, Ramsay G, Alitalo K, Varmus HE, Bishop JM, Martinsson T, Levan G, Levan A: Application and enhanced expression of the c-myc oncogene in mouse SEWA tumour cells. Nature 315: 345–347, 1985
- 42 Seshadri R, Matthews C, Dobrovic A, Horsfall DJ: The significance of oncogene amplification in primary breast cancer. Int J Cancer 43: 270–272, 1989
- 43 Shin DM, Gupta V, Donner L, Chawla S, Benjamin R, Gutterman J, Blick M: Aberrant oncogene expression in uncultured human sarcoma and melanoma. Anticancer Res 7: 1117–1123, 1987
- 44 Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98: 503–517, 1975
- 45 Tatosyan AG, Galetzki SA, Kisseljova NP, Asanova AA, Zborovskaya IB, Spitkovsky DD, Revasova ES, Martin P, Kisseljov FL: Oncogene expression in human tumors. Int J Cancer 35: 731–736, 1985
- 46 Tribukait B: Clinical DNA flow cytometry. Med Oncol Tumor Pharmacother 1: 211–218, 1984
- 47 Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery JP, Olschwang S, Philip I, Berger MP, Philip T, Lenoir GM, Mazabraud A: Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24:q12). Cancer Genet Cytogenet 32: 229–238, 1988
- 48 Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2 (neu) or c-myc protooncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1: 423–431, 1987
- 49 Wang L, Vass W, Gao CL, Chang KS: Amplification and enhanced expression of the c-Ki-ras2 protooncogene in human embryonal carcinomas. Cancer Res 47: 4192–4198, 1987
- 50 Watt R, Stanton LW, Marcu KB, Gallo RC, Croce CM, Rovera G: Nucleotide sequence of cloned cDNA of human c-myc oncogene. Nature 303: 725–728, 1983
- 51 Yokota J, Tsunetsugu-Yokota Y, Battifora H, Le-Fevre C, Cline MJ: Alterations of myc, myb and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science 231: 261–265, 1986
- 52 Zhou D, Battifora H, Yokota J, Yamamoto, Cline MJ: Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 47: 6123–6125, 1987